Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARK: Omalizumab for Preventing Asthma Progression in Kids
NCT02570984Phase 2Active, not recruiting
- Sponsor
- Boston Children's Hospital
- Start
- Nov 2018
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omalizumab in asthma (2 arms), sponsored by Boston Children's Hospital. Primary endpoints: Active Asthma Diagnosis and Asthma Severity. Started Nov 2018; status: active, not recruiting.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02570984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02570984.